Literature DB >> 12409978

Angiotensin-(1-7) inhibits angiotensin II-induced signal transduction.

Zhiming Zhu1, Jian Zhong, Shanjun Zhu, Daoyan Liu, Markus Van Der Giet, Martin Tepel.   

Abstract

The inhibitory effects of angiotensin-(1-7) on angiotensin II-induced vasoconstriction, growth of vascular smooth muscle cells, stimulation of protein kinase C, extracellular signal-regulated kinases (ERK), and angiotensin subtype 1 receptor (AT1) and subtype 2 receptor (AT2) mRNA expression were investigated. The hemodynamic effects of angiotensin-(1-7) were measured in Wistar rats. Vasoconstriction was measured using aortic rings. DNA synthesis or protein synthesis was measured in cultured vascular smooth muscle cells using [3H] thymidine or [3H] leucine incorporation, respectively. Angiotensin II stimulated protein kinase C and ERK1/2 were measured by Western blot analysis using phosphospecific protein kinase C and ERK1/2 antibodies. AT1 and AT2 receptor mRNA expression was measured using reverse-transcription polymerase chain reaction. Infusion of angiotensin II significantly increased whereas infusion of angiotensin-(1-7) had no effects on mean arterial blood pressure in Wistar rats. Angiotensin-(1-7) dose-dependently showed partial antagonism on angiotensin II-induced contraction of aortic rings. Angiotensin-(1-7) showed partial antagonism on angiotensin II-induced DNA synthesis and protein synthesis. Angiotensin-(1-7) showed partial antagonism on angiotensin II-induced activation of protein kinase C and ERK1/2. The administration of angiotensin-(1-7) showed partial antagonism on angiotensin II-induced downregulation of AT1 receptor mRNA expression, whereas AT2 receptor mRNA expression was unchanged. Angiotensin-(1-7) showed partial antagonism on angiotensin II-induced intracellular signal transduction and may play a crucial role in the adaptation process of AT1 receptors to sustained stimulation of angiotensin II.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12409978     DOI: 10.1097/00005344-200211000-00007

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

Review 1.  Angiotensin-(1-7) as an antihypertensive, antifibrotic target.

Authors:  Michael J Katovich; Justin L Grobe; Mohan K Raizada
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

Review 2.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

3.  Effects of ACE2 inhibition in the post-myocardial infarction heart.

Authors:  Myung-A Kim; Dongheon Yang; Keisuke Kida; Natalia Molotkova; Seon Ju Yeo; Nissi Varki; Michikado Iwata; Nancy D Dalton; Kirk L Peterson; Wolf-Eberhard Siems; Thomas Walther; Randy T Cowling; John Kjekshus; Barry Greenberg
Journal:  J Card Fail       Date:  2010-05-23       Impact factor: 5.712

4.  Elevated endothelial nitric oxide bioactivity and resistance to angiotensin-dependent hypertension in 12/15-lipoxygenase knockout mice.

Authors:  Peter B Anning; Barbara Coles; Alexandra Bermudez-Fajardo; Patricia E M Martin; Bruce S Levison; Stanley L Hazen; Colin D Funk; Hartmut Kühn; Valerie B O'Donnell
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

5.  Complete blockade of the vasorelaxant effects of angiotensin-(1-7) and bradykinin in murine microvessels by antagonists of the receptor Mas.

Authors:  Concepción Peiró; Susana Vallejo; Florian Gembardt; Erika Palacios; Susana Novella; Verónica Azcutia; Leocadio Rodríguez-Mañas; Carlos Hermenegildo; Carlos F Sánchez-Ferrer; Thomas Walther
Journal:  J Physiol       Date:  2013-03-04       Impact factor: 5.182

6.  Defects in cutaneous angiotensin-converting enzyme 2 and angiotensin-(1-7) production in postural tachycardia syndrome.

Authors:  Julian M Stewart; Anthony J Ocon; Debbie Clarke; Indu Taneja; Marvin S Medow
Journal:  Hypertension       Date:  2009-03-16       Impact factor: 10.190

Review 7.  Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension.

Authors:  Rodrigo Araujo Fraga-Silva; Anderson Jose Ferreira; Robson Augusto Souza Dos Santos
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

8.  Role of Mas Receptor Antagonist A799 in Renal Blood Flow Response to Ang 1-7 after Bradykinin Administration in Ovariectomized Estradiol-Treated Rats.

Authors:  Aghdas Dehghani; Shadan Saberi; Mehdi Nematbakhsh
Journal:  Adv Pharmacol Sci       Date:  2015-09-03

9.  Anti-Inflammatory Action of Angiotensin 1-7 in Experimental Colitis.

Authors:  Maitham A Khajah; Maryam M Fateel; Kethireddy V Ananthalakshmi; Yunus A Luqmani
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

10.  Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome.

Authors:  Jian Zhong; Zhengchen Yan; Daoyan Liu; Yinxing Ni; Zhigang Zhao; Shanjun Zhu; Martin Tepel; Zhiming Zhu
Journal:  J Lab Clin Med       Date:  2006-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.